Evidence map›Paper›PMID 40599446›Full record

ReviewArchives of Razi Institute2024

Comprehensive Analysis of

A Naseri, A Matoofi, M Mansouri Ramezani, L Kalantari, T Taherzadeh Amlashi, S Roudaki, M Mohammadian, A Omranzadeh

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Archives of Razi Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. HarnessingArchives of Razi Institute · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A NaseriMedical doctor, Mashhad University of Medical Sciences, Mashhad, Iran.
A MatoofiDepartment of Radiation Oncology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
M Mansouri RamezaniMedical doctor, Golestan University of Medical Science, Gorgan, Iran.
L KalantariMedical doctor, Kashan University of Medical Science, Kashan, Iran.
T Taherzadeh AmlashiMedical doctor, Guilan University of Medical Sciences, Guilan, Iran.
S RoudakiPharmacist, Shiraz University of Medical Sciences, Shiraz, Iran.
M MohammadianMedical doctor, Mashhad University of Medical Sciences, Mashhad, Iran.
A OmranzadehMedical doctor, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The risk of cancer development posed by papillomavirus (PV) infections is significant, affecting both humans and domestic animals. This underscores the importance of understanding and addressing this viral threat. Recent research has demonstrated the potential of immunotherapies, particularly immune checkpoint blockers (ICBs), in enhancing the immune response against tumor-associated antigens (TAAs) and tumor-related neoantigens, thereby facilitating their neutralization by the immune system. Furthermore, vaccines designed to enhance the immune response against PV-infected cells have yielded promising results, strengthening CD

Indexed as

NeoplasmsPapillomaviridaePapillomavirus InfectionsAnimalsHumansImmunotherapyPapillomavirus VaccinesVeterinary MedicinePapillomavirus VaccinesCancer ImmunotherapyOncogenic MechanismsPapillomavirusTherapeutic StrategiesVirus

Identifiers

PMID40599446
PMCPMC12207925

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.